Trial Profile
A study of axitinib for biliary tract cancer refractory to gemcitabine-based chemotherapy
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 19 May 2021
Price :
$35
*
At a glance
- Drugs Axitinib (Primary)
- Indications Adenocarcinoma; Adenosquamous carcinoma; Biliary cancer; Cholangiocarcinoma; Gallbladder cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms AX-BC
- 01 Feb 2021 Status has been changed to discontinued, as per Results published in the Oncologist
- 14 Jan 2019 Status changed from suspended to completed.
- 08 Sep 2017 Status changed from recruiting to suspended.